Kailo Pharma

Company Overview

Snapshot

Founded in February 2026 by Dr. Iris Reuveni and Prof. Edi Barkai, Kailo Pharma is an early-stage company with 1–10 employees. The company has raised $2.1M across one funding round from two investors. In March 2026, Kailo Pharma secured Pre-Seed funding from NGT HealthCare II.

Business overview

Kailo Pharma is an Israeli medical startup focused on developing a novel treatment for Post-Traumatic Stress Disorder (PTSD). The company is commercializing research from the University of Haifa, targeting a newly identified brain mechanism responsible for the pathological amplification of traumatic memories. Kailo Pharma's core technology involves a peptide-based therapy designed for nasal delivery, aiming to reach the central nervous system to weaken trauma intensity without affecting normal memory. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the healthcare and life sciences industries.

Strategic signal

In March 2026, Kailo Pharma secured Pre-Seed funding, led by. This investment validates the potential of the company's novel approach, which targets a specific brain mechanism to weaken traumatic memories without erasing normal memory. For investors, this signals early confidence in a differentiated therapeutic strategy within the mental health and neuroscience space, positioning Kailo Pharma for continued preclinical development and potential future clinical trials.

Company Intelligence Q&A

What is Kailo Pharma's primary focus?

Kailo Pharma is focused on developing a peptide-based nasal spray for the direct treatment of Post-Traumatic Stress Disorder (PTSD), targeting a newly identified brain mechanism.

When was Kailo Pharma founded and by whom?

Kailo Pharma was founded in February 2026 by Dr. Iris Reuveni and Prof. Edi Barkai.

What was Kailo Pharma's most recent funding event?

In March 2026, Kailo Pharma secured Pre-Seed funding from NGT HealthCare II and Israel Innovation Authority.

What is the total capital raised by Kailo Pharma?

Kailo Pharma has raised a total of $2.1M across one funding round.

What is the core technology behind Kailo Pharma's treatment?

Kailo Pharma is developing a peptide-based therapy intended for nasal delivery to reach the central nervous system, aiming to weaken trauma intensity without erasing normal memory.